Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Fmr LLC

Fmr LLC raised its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 29.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,822,275 shares of the biotechnology company’s stock after acquiring an additional 1,767,714 shares during the period. Fmr LLC owned approximately 13.86% of Astria Therapeutics worth $86,123,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Rhumbline Advisers raised its holdings in shares of Astria Therapeutics by 4.1% during the second quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 2,556 shares during the last quarter. Quest Partners LLC grew its position in Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,112 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Astria Therapeutics by 6.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock valued at $1,266,000 after buying an additional 8,965 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Astria Therapeutics in the 3rd quarter valued at about $155,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Astria Therapeutics in the first quarter worth about $200,000. 98.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ATXS. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a report on Tuesday, August 13th. Oppenheimer increased their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Astria Therapeutics has an average rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Trading Down 3.8 %

Shares of Astria Therapeutics stock opened at $9.75 on Friday. Astria Therapeutics, Inc. has a twelve month low of $4.87 and a twelve month high of $16.90. The firm’s 50-day moving average price is $10.98 and its 200 day moving average price is $10.64. The firm has a market capitalization of $550.19 million, a PE ratio of -4.67 and a beta of 0.67.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.